

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

---

**BEFORE THE PATENT TRIAL AND APPEAL BOARD**

---

COALITION FOR AFFORDABLE DRUGS VIII, LLC  
Petitioner

v.

TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA  
Patent Owner, based on Electronic Records of PTO

U.S. Patent No. 7,932,268 B2 to Rader

Filing Date: March 7, 2005

Issue Date: April 26, 2011

TITLE: METHODS FOR TREATING DISORDERS OR DISEASES ASSOCIATED  
WITH HYPERLIPIDEMIA AND HYPERCHOLESTEROLEMIA WHILE  
MINIMIZING SIDE EFFECTS

---

*Inter Partes* Review Trial No. TBD

---

**Declaration of Michael Mayersohn, Ph.D. in Support of Coalition for  
Affordable Drugs' Petition for  
*Inter Partes* Review of U.S. Patent No. 7,932,268 B2**

## TABLE OF CONTENTS

I.	INTRODUCTION.....	1
II.	QUALIFICATIONS AND BACKGROUND.....	1
III.	SUMMARY OF THIS REPORT.....	5
IV.	LIST OF MATERIALS CONSIDERED.....	7
	A.    Chang.....	7
	B.    The Pink Sheet.....	8
	C.    Stein 2004.....	9
V.	PERSON OF ORDINARY SKILL IN THE ART.....	10
VI.	SCIENTIFIC AND TECHNICAL BACKGROUND.....	11
	A.    Pharmacokinetics.....	11
	B.    B. Multiple Dosing and Steady State.....	12
	C.    Using Drug Doses within a Drug Class to Propose Dosing.....	17
VII.	MTP INHIBITORS GENERALLY.....	19
VIII.	IMPLITAPIDE AND ITS APPLICATION TO LOMITAPIDE.....	20
	A.    Efficacy and Side Effects.....	20
	B.    Animal Models.....	22
	C.    Human Studies.....	25
	D.    Pink Sheet Teachings Pertinent to Lomitapide Dosing.....	27
	E.    Stein 2004 Teachings Pertinent to Lomitapide Dosing.....	28
	F.    Lomitapide Dosing Based on the Pink Sheet in view of Chang.....	29
	G.    Lomitapide Dosing Based on Stein 2004 in view of Chang.....	30

Declaration of Michael Mayersohn, Ph.D.  
Petition for *Inter Partes* Review of U.S. Patent No. 7,932,268

IX.	THE '915 PROVISIONAL DOES NOT TEACH THE CLAIMED ESCALATING DOSE RANGES.....	34
X.	CONCLUSION.....	50

### TABLE OF EXHIBITS

Exhibit	Title
CFAD 1001	Certified U.S. Patent No. 7,932,268.
CFAD 1002	Declaration of Randall M. Zusman, M.D.
CFAD 1005	Affidavit of Christopher Butler, Office Manager, Internet Archive, authenticating Internet Archive URLs (June 12, 2015) (attaching as Ex. A:  <i>PPD News Releases(2004/02/13)</i> (available at <a href="https://web.archive.org/web/20040213233245/http://www.ppd.com/PPD_U6.htm?ID=126662">https://web.archive.org/web/20040213233245/http://www.ppd.com/PPD_U6.htm?ID=126662</a> );  <i>PPD News &amp; IR Presentations(2003/12/12)</i> (available at <a href="https://web.archive.org/web/20031212193444/http://ppdi.com/PPD_6_12.htm">https://web.archive.org/web/20031212193444/http://ppdi.com/PPD_6_12.htm</a> );  <i>PPD News &amp; IR Presentations (2004/06/04)</i> (available at <a href="https://web.archive.org/web/20040604203252/http://www.ppd.com/PPD_6_12.htm">https://web.archive.org/web/20040604203252/http://www.ppd.com/PPD_6_12.htm</a> )).
CFAD 1006	Certified U.S. Provisional Patent Application No. 60/550,915.
CFAD 1007	U.S. Patent No. 7,932,268 (highlighting dosing information not present in U.S. Provisional Patent Application No. 60/550,915).
CFAD 1013	<i>Bayer/PPD Implitapide Development Follows Zetia Model As Statin Add-On</i> , 66 THE PINK SHEET 17 (Feb. 16, 2004).
CFAD 1014	Evan Stein, CEO & President, MRL Int'l (Division of PPD), Presentation Given at PPD's Analyst Day, <i>Microsomal Triglyceride [sic] Transfer Protein (MTP) Inhibitor (implitapide) program</i> (Feb. 5, 2004).
CFAD 1015	George Chang et al., <i>Microsomal triglyceride transfer protein (MTP) inhibitors: Discovery of clinically active inhibitors using high-throughput screening and parallel synthesis paradigms</i> , 5 CURRENT OPINION IN DRUG DISCOVERY & DEV. 562 (2002).

Declaration of Michael Mayersohn, Ph.D.  
Petition for *Inter Partes* Review of U.S. Patent No. 7,932,268

CFAD 1016	Charles E. Chandler et al., <i>CP-346086: an MTP inhibitor that lowers plasma cholesterol and triglycerides in experimental animals and in humans</i> , 44 J. OF LIPID RES. 1887 (2003).
CFAD 1018	John R. Wetterau et al., <i>An MTP Inhibitor That Normalizes Atherogenic Lipoprotein Levels in WHHL Rabbits</i> , 282 SCI. 751 (1998).
CFAD 1023	U.S. FOOD & DRUG ASS'N, ESTIMATING THE MAXIMUM SAFE STARTING DOSE IN INITIAL CLINICAL TRIALS FOR THERAPEUTICS IN ADULT HEALTHY VOLUNTEERS: GUIDANCE FOR INDUSTRY (2005).
CFAD 1026	Rowland & Tozer, <i>Clinical Pharmacokinetics: Concepts and Applications</i> , 58, 98 (1995)
CFAD 1029	Michael Mayersohn. Ph.D. Curriculum Vitae
CFAD 1032	M. Mayersohn, <i>Principles and Applications of Pharmacokinetics</i> , in MEDICAL TOXICOLOGY, 282 (2004)
CFAD 1033	Shiomi & Ito, "MTP inhibitor decreases plasma cholesterol levels in LDL receptor-deficient WHHL rabbits by lowering the VLDL secretion," <i>European Journal of Pharmacology</i> , 431:127-131 (2001)
CFAD 1038	Margaret A. McDowell et al., <i>Anthropometric Reference Data for Children and Adults: U.S. Population, 1999-2002</i> , CDC ADVANCE DATA FROM VITAL & HEALTH STATS. NO. 361 (2005)

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.